• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A phase I study of the myeloid cell leukemia 1 (MCL1) inhibitor tapotoclax (AMG 176) in patients with myelodysplastic syndromes after hypomethylating agent failure.

作者信息

Chien Kelly S, Rodriguez-Sevilla Juan Jose, Alvarado Yesid, Montalban-Bravo Guillermo, Hammond Danielle E, Swaminathan Mahesh, Bazinet Alexandre, Kimberley Jacqueline, Bodden Kristy, Schneider Heather, Dong Xiao Qin, Pierce Sherry A, Huang Xuelin, Jabbour Elias J, Kantarjian Hagop M, Garcia-Manero Guillermo

机构信息

The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX, USA.

The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX, USA.

出版信息

Leuk Res. 2024 Dec;147:107602. doi: 10.1016/j.leukres.2024.107602. Epub 2024 Oct 22.

DOI:10.1016/j.leukres.2024.107602
PMID:39461095
Abstract
摘要

相似文献

1
A phase I study of the myeloid cell leukemia 1 (MCL1) inhibitor tapotoclax (AMG 176) in patients with myelodysplastic syndromes after hypomethylating agent failure.一项关于髓系细胞白血病1（MCL1）抑制剂他泊托克拉（AMG 176）在去甲基化药物治疗失败的骨髓增生异常综合征患者中的I期研究。
Leuk Res. 2024 Dec;147:107602. doi: 10.1016/j.leukres.2024.107602. Epub 2024 Oct 22.
2
Selective inhibition of MCL1 overcomes venetoclax resistance in a murine model of myelodysplastic syndromes.选择性抑制 MCL1 可克服骨髓增生异常综合征小鼠模型中的 venetoclax 耐药性。
Haematologica. 2023 Feb 1;108(2):522-531. doi: 10.3324/haematol.2022.280631.
3
A multitier virtual screening study of phytoconstituents as Myeloid Cell Leukemias 1 inhibitors.植物成分作为髓系细胞白血病 1 抑制剂的多层次虚拟筛选研究。
J Biomol Struct Dyn. 2024 Jul;42(10):5219-5228. doi: 10.1080/07391102.2023.2226739. Epub 2023 Jul 7.
4
Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis.骨髓增生异常综合征后急性髓系白血病及低甲基化药物治疗失败：一种预后不良的新出现的实体。
Clin Lymphoma Myeloma Leuk. 2014 Apr;14(2):93-7. doi: 10.1016/j.clml.2013.10.013. Epub 2013 Nov 15.
5
Dynamics of PD-1 expression are associated with treatment efficacy and prognosis in patients with intermediate/high-risk myelodysplastic syndromes under hypomethylating treatment.PD-1 表达的动态变化与低甲基化药物治疗中/高危骨髓增生异常综合征患者的疗效和预后相关。
Front Immunol. 2022 Aug 8;13:950134. doi: 10.3389/fimmu.2022.950134. eCollection 2022.
6
A sequential two-stage dose escalation study of eltrombopag in patients with myelodysplastic syndrome and thrombocytopenia after hypomethylating agent failure.在低甲基化药物治疗失败后，伴有血小板减少的骨髓增生异常综合征患者接受艾曲泊帕的序贯两阶段剂量递增研究。
Leuk Lymphoma. 2020 Aug;61(8):1901-1907. doi: 10.1080/10428194.2020.1751841. Epub 2020 Apr 19.
7
Hypomethylating Chemotherapeutic Agents as Therapy for Myelodysplastic Syndromes and Prevention of Acute Myeloid Leukemia.去甲基化化疗药物治疗骨髓增生异常综合征及预防急性髓系白血病
Pharmaceuticals (Basel). 2021 Jul 4;14(7):641. doi: 10.3390/ph14070641.
8
A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents.一项多中心 Ib 期临床试验，评估组蛋白去乙酰化酶抑制剂恩替诺特与帕博利珠单抗联合用于对低甲基化药物难治的骨髓增生异常综合征/肿瘤或急性髓系白血病患者的疗效。
Ann Hematol. 2024 Jan;103(1):105-116. doi: 10.1007/s00277-023-05552-4. Epub 2023 Dec 1.
9
Decitabine in the treatment of myelodysplastic syndromes.地西他滨治疗骨髓增生异常综合征。
Ther Clin Risk Manag. 2007 Oct;3(5):807-17.
10
The development and clinical use of oral hypomethylating agents in acute myeloid leukemia and myelodysplastic syndromes: dawn of the total oral therapy era.口服低甲基化剂在急性髓系白血病和骨髓增生异常综合征中的研发和临床应用：全口服治疗时代的曙光。
Expert Rev Anticancer Ther. 2021 Sep;21(9):989-1002. doi: 10.1080/14737140.2021.1918002. Epub 2021 Apr 28.

引用本文的文献

1
Multidrug Resistance: Are We Still Afraid of the Big Bad Wolf.多重耐药性：我们还怕那只大坏狼吗？
Pharmaceuticals (Basel). 2025 Jun 14;18(6):895. doi: 10.3390/ph18060895.